Carbimazole and the autoimmune response in Graves' disease.

@article{Mcgregor1980CarbimazoleAT,
  title={Carbimazole and the autoimmune response in Graves' disease.},
  author={A. M. Mcgregor and Michael M{\o}rk Petersen and S. M. Mclachlan and P Rooke and Bernard Rees Smith and Reginald Hall},
  journal={The New England journal of medicine},
  year={1980},
  volume={303 6},
  pages={
          302-7
        }
}
Microsomal antibodies and antibodies directed toward the receptor for thyroid-stimulating hormone (TSH) decreased in parallel while patients with Graves' disease were taking carbimazole, whereas no significant changes were observed during treatment with placebo or propranolol. The changes in autoantibody levels during carbimazole treatment were independent of changes in serum thyroxine and could have been due to a direct effect of the drug on autoantibody synthesis. Evidence for this suggestion… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 42 CITATIONS

Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes.

  • The Journal of endocrinology
  • 2007
VIEW 4 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Long-term remission following antithyroid drug withdrawal in patients with Graves’ hyperthyroidism: parameters with prognostic value

Ricardo V. García-Mayor, Paula Álvarez-Vázquez, Enrique Fluiters, Diana Valverde, Amalia Andrade
  • Endocrine
  • 2018
VIEW 1 EXCERPT
CITES RESULTS